July 25, 2024
Postmenopausal Osteoporosis Market

The Growing Prevalence of Osteoporosis is anticipated to open up the new avenues for Postmenopausal Osteoporosis Market

The Postmenopausal Osteoporosis Market is estimated to be valued at US$ 4,747.9 Mn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Postmenopausal osteoporosis refers to the porous and brittle condition of the bones which occurs in women after menopause. Weakening of bones makes them prone to fractures. The major products available in the market for postmenopausal osteoporosis treatment include bisphosphonates, selective estrogen receptor modulators (SERMs), monoclonal antibodies and anabolics. These drugs slow down bone loss and increase bone mineral density, thereby reducing the risk of fractures.

Market Dynamics:
The growing prevalence of osteoporosis among postmenopausal women is expected to drive the market growth over the forecast period. As per International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures annually worldwide, impacting fragility fractures and chronic pain.
Furthermore, increasing geriatric population also favors market growth. According to the United Nations, the world’s population aged 60 years and older numbered 962 million in 2017 and by 2050, it is projected to reach nearly 2.1 billion, up from about 962 million in 2017. Fragility fractures are common in the elderly due to low bone mineral density associated with aging. Growing awareness regarding osteoporosis diagnosis and treatment is also expected to boost the market growth during the forecast period.
Segment Analysis
The postmenopausal osteoporosis market is dominated by the bone-forming drug segment. Within bone-forming drug class, bisphosphonates occupy leading share due to their high potency to rebuild bone loss and prevent fractures. Other major segments include calcitonin, selective estrogen receptor modulators (SERMs), and monoclonal antibodies, amongst which monoclonal antibodies segment is expected to witness fastest growth over the forecast period owing to their targeted mechanism of action to inhibit bone resorption by blocking certain proteins.

PEST Analysis
Political: Governments across world are supporting osteoporosis and bone health campaigns to spread awareness regarding disease prevention. Additionally, favorable reimbursement policies boost the consumption of drugs.
Economic: Rising geriatric population worldwide increasing the demand for osteoporosis treatment. However, high cost of branded drugs remains a concern.
Social: Growing health consciousness among aging population and support from community programs regarding bone health drives the market growth.
Technological: Advancements in drug delivery and screening techniques help in developing novel anabolic and anti-resorptive agents with better efficacy and safety profile.

Key Takeaways
The global Postmenopausal Osteoporosis Market Growth is expected to witness high growth, exhibiting CAGR of 4.4% over the forecast period, due to increasing geriatric population and prevalence of postmenopausal osteoporosis worldwide.

The Asia Pacific region is projected to be the fastest growing market for postmenopausal osteoporosis due to rising healthcare expenditure and increasing awareness. Moreover, large base of aging population in China and India provides huge patient base for osteoporosis drugs in the region.

Key players operating in the postmenopausal osteoporosis market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING, Amgen, Gedeon Richter Plc. Enzene Biosciences, Samsung BioepisL Radius Health, Inc., Alvotech, and AryoGen Pharmed.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it